Blood-based biomarkers have the potential to revolutionize clinical practice and clinical trials in Alzheimer disease (AD). However, to date, this “holy grail” opportunity has not been realized owing to a broad range of issues, including the lack of a clearly defined context of use (COU), lack of standardization of methods, and numerous failures at replication. Recently, however, a shift in the paradigm has occurred, with my colleagues and I proposing specific COUs for blood-based biomarkers along with potential paradigms for advancing from discovery to clinic and potential acceptable standards.1,2
Through her research and volunteering, Rebecca Ehrenkranz is hoping to aid those around her
Rebecca Ehrenkranz volunteers with Repair the World Pittsburgh. Photo courtesy of Repair the World Pittsburgh Those seeking a healthy brain stand to benefit from Rebecca Ehrenkranz’s research. For the past three years, the University of Pittsburgh graduate student and...
